298 related articles for article (PubMed ID: 34244291)
1. Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung Cancer.
Luo J; Martucci VL; Quandt Z; Groha S; Murray MH; Lovly CM; Rizvi H; Egger JV; Plodkowski AJ; Abu-Akeel M; Schulze I; Merghoub T; Cardenas E; Huntsman S; Li M; Hu D; Gubens MA; Gusev A; Aldrich MC; Hellmann MD; Ziv E
Clin Cancer Res; 2021 Sep; 27(18):5131-5140. PubMed ID: 34244291
[TBL] [Abstract][Full Text] [Related]
2. Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer.
Zhou Y; Xia R; Xiao H; Pu D; Long Y; Ding Z; Liu J; Ma X
Int Immunopharmacol; 2021 Feb; 91():107296. PubMed ID: 33360368
[TBL] [Abstract][Full Text] [Related]
3. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
[TBL] [Abstract][Full Text] [Related]
4. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
[TBL] [Abstract][Full Text] [Related]
5. Do endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab?
Chmielewska I; Dudzińska M; Szczyrek M; Świrska J; Wojas-Krawczyk K; Zwolak A
PLoS One; 2021; 16(9):e0257484. PubMed ID: 34587185
[TBL] [Abstract][Full Text] [Related]
6. Predictors of thyroid adverse events during cancer immunotherapy: a real-life experience at a single center.
Ruggeri RM; Spagnolo CC; Alibrandi A; Silvestris N; Cannavò S; Santarpia M
J Endocrinol Invest; 2023 Nov; 46(11):2399-2409. PubMed ID: 37076759
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
Kotwal A; Kottschade L; Ryder M
Thyroid; 2020 Feb; 30(2):177-184. PubMed ID: 31813343
[No Abstract] [Full Text] [Related]
8. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.
Sato K; Akamatsu H; Murakami E; Sasaki S; Kanai K; Hayata A; Tokudome N; Akamatsu K; Koh Y; Ueda H; Nakanishi M; Yamamoto N
Lung Cancer; 2018 Jan; 115():71-74. PubMed ID: 29290265
[TBL] [Abstract][Full Text] [Related]
9. Higher baseline TSH levels predict early hypothyroidism during cancer immunotherapy.
Luongo C; Morra R; Gambale C; Porcelli T; Sessa F; Matano E; Damiano V; Klain M; Schlumberger M; Salvatore D
J Endocrinol Invest; 2021 Sep; 44(9):1927-1933. PubMed ID: 33576954
[TBL] [Abstract][Full Text] [Related]
10. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
11. Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
Hosoya K; Fujimoto D; Morimoto T; Kumagai T; Tamiya A; Taniguchi Y; Yokoyama T; Ishida T; Hirano K; Matsumoto H; Kominami R; Tomii K; Suzuki H; Hirashima T; Uchida J; Morita M; Kanazu M; Sawa N; Makio T; Hara S; Tamiya M
Clin Lung Cancer; 2020 Jul; 21(4):e315-e328. PubMed ID: 32113737
[TBL] [Abstract][Full Text] [Related]
12. Thyroid dysfunction after immune checkpoint inhibitor treatment in a single-center Chinese cohort: a retrospective study.
Wu L; Xu Y; Wang X; Cheng X; Zhang Y; Wang Y; Fan X; Zhao H; Liu H; Chai X; Zhang L; Wang M; Li N; Pan H; Lian X
Endocrine; 2023 Jul; 81(1):123-133. PubMed ID: 36867366
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab-induced thyroid dysfunction in patients with lung cancer.
Ramos-Levi AM; Rogado J; Sanchez-Torres JM; Colomer R; Marazuela M
Endocrinol Diabetes Nutr (Engl Ed); 2019 Jan; 66(1):26-34. PubMed ID: 29910159
[TBL] [Abstract][Full Text] [Related]
14. A Population-based Study of Immunotherapy-related Toxicities in Lung Cancer.
Cathcart-Rake EJ; Sangaralingham LR; Henk HJ; Shah ND; Riaz IB; Mansfield AS
Clin Lung Cancer; 2020 Sep; 21(5):421-427.e2. PubMed ID: 32446852
[TBL] [Abstract][Full Text] [Related]
15. Correlation between immune-related adverse events and the efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: systematic review and meta-analysis.
Zhang Q; Wang W; Yuan Q; Li L; Wang YC; Chi CZ; Xu CH
Cancer Chemother Pharmacol; 2022 Jan; 89(1):1-9. PubMed ID: 34821962
[TBL] [Abstract][Full Text] [Related]
16. Thyroid Immune-Related Adverse Events in Patients with Cancer Treated with anti-PD1/anti-CTLA4 Immune Checkpoint Inhibitor Combination: Clinical Course and Outcomes.
Lui DTW; Lee CH; Tang V; Fong CHY; Lee ACH; Chiu JWY; Leung RCY; Kwok GGW; Li BCW; Cheung TT; Woo YC; Lam KSL; Yau T
Endocr Pract; 2021 Sep; 27(9):886-893. PubMed ID: 33581327
[TBL] [Abstract][Full Text] [Related]
17. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer.
Osorio JC; Ni A; Chaft JE; Pollina R; Kasler MK; Stephens D; Rodriguez C; Cambridge L; Rizvi H; Wolchok JD; Merghoub T; Rudin CM; Fish S; Hellmann MD
Ann Oncol; 2017 Mar; 28(3):583-589. PubMed ID: 27998967
[TBL] [Abstract][Full Text] [Related]
18. Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis.
Cheung YM; Wang W; McGregor B; Hamnvik OR
Cancer Immunol Immunother; 2022 Aug; 71(8):1795-1812. PubMed ID: 35022907
[TBL] [Abstract][Full Text] [Related]
19. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
[TBL] [Abstract][Full Text] [Related]
20. Association of Systemic Steroid Treatment and Outcome in Patients Treated with Immune Checkpoint Inhibitors: A Real-World Analysis.
Paderi A; Gambale E; Botteri C; Giorgione R; Lavacchi D; Brugia M; Mazzoni F; Giommoni E; Bormioli S; Amedei A; Pillozzi S; Matucci Cerinic M; Antonuzzo L
Molecules; 2021 Sep; 26(19):. PubMed ID: 34641331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]